Key result
Severe hypertriglyceridemia presents significant diagnostic and therapeutic challenges, highlighting the need for novel therapies like ASO and siRNA targeting ApoC3 and ANGPTL3/8.
Why the study?
Severe hypertriglyceridemia and chylomicronaemia present significant diagnostic and therapeutic challenges, necessitating exploration of their aetiopathogenesis, complications, and novel management options.
Design
Review
Authors
Loading...
Supports further development of ApoC3/ANGPTL3-targeted therapies; leaves open their efficacy and safety in severe hypertriglyceridemia.
Severe hypertriglyceridemia presents significant diagnostic and therapeutic challenges, with novel RNA-targeted therapies offering promising new avenues for management.
Bashir et al. (2024) conducted a review in Severe hypertriglyceridaemia (SHTG) and chylomicronaemia. Antisense oligonucleotides (ASO) and short interfering RNA (siRNA) targeting ApoC3 and ANGPTL3/8 vs. Conventional lipid-lowering medications was evaluated. Severe hypertriglyceridemia presents significant diagnostic and therapeutic challenges, highlighting the need for novel therapies like ASO and siRNA targeting ApoC3 and ANGPTL3/8.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: